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a b s t r a c t 
Chemotherapy-induced peripheral neuropathy (CIPN) is a fre- 
quent and potentially irreversible adverse event of cytotoxic 
chemotherapy. We evaluate whether sensory neurons de- 
rived from induced pluripotent stem cells (iPSC-DSN) can 
serve as human disease model system for chemotherapy 
induced neurotoxicity. Sensory neurons differentiated from 
two established induced pluripotent stem cell lines were 
used (s.c. BIHi0 05-A https://hpscreg.eu/cell-line/BIHi0 05-A 
and BIHi0 04-B https://hpscreg.eu/cell-line/BIHi0 04-B , Berlin 
Institute of Health Stem Cell Core Facility). Cell viability 
and cytotoxicity assays were performed, comparing suscep- 
tibility to four neurotoxic and two non-neurotoxic drugs. 
RNA sequencing analyses in paclitaxel vs. vehicle (DMSO)- 
treated sensory neurons were performed. Treatment of iPSC- 
DSN for 24 h with the neurotoxic drugs paclitaxel, borte- 
zomib, vincristine and cisplatin led to a dose dependent de- 
cline of cell viability in clinically relevant IC 50 ranges, which 
was not the case for the non-neurotoxic compounds doxoru- 
bicin and 5-fluorouracil. RNA sequencing analyses at 24 h, 
i.e. before paclitaxel-induced cell death occurred, revealed 
the differential expression of genes of neuronal injury, cel- 
lular stress response, and sterol pathways in response to 
1 μM paclitaxel. Neuroprotective effects of lithium chloride 
co-incubation, which were previously shown in rodent dor- 
sal root ganglia, could be replicated in human iPSC-DSN. Cell 
lines from the two different donors BIHi005-A and BIHi004- 
B showed different responses to the neurotoxic treatment in 
cell viability and cytotoxicity assays. 
© 2021 The Authors. Published by Elsevier Inc. 
This is an open access article under the CC BY-NC-ND 
license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
Specifications Table 
Subject Neuroscience: Cellular and Molecular 
Specific subject area Experimental neurology and disease modeling 





How data were acquired MTT-based cell viability and proteases-based cytotoxicity assays. RNA 
sequencing analyses. 
Data format Raw data 
Analyzed 
Parameters for data collection Data were collected from experiments using induced pluripotent stem cell 
derived sensory neurons. 
( continued on next page ) 































Description of data collection Data were collected from different cell viability and cytotoxicity assays based 
on signal detection by fluorescence, luminescence and absorbance readers. 
RNA sequencing analyses were performed as described in the manuscript [1] . 
Data source location Institution: Charité - Universitätsmedizin Berlin 
City/Town/Region: Berlin 
Country: Germany 
Data accessibility With the article 
Related research article Co-submission: 
Schinke et al. Modeling chemotherapy induced neurotoxicity with human induced 
pluripotent stem cell (iPSC) -derived sensory neurons. Neurobiology of disease 
2021. https://doi.org/10.1016/j.nbd.2021.105391 [1] . 
Value of the Data 
• These data give insight into the pathomechanisms of chemotherapy induced neurotoxic-
ity modeled with human induced pluripotent stem cell derived sensory neurons of two
healthy donors, applying cell viability and cytotoxicity assays and differential RNA sequencing
analyses. 
• Basic scientists, clinician scientists, biostatisticians and toxicologists will benefit from these
data. 
• The shared data give insight into transcriptional changes of sensory neurons in response to
paclitaxel treatment. They may help scientists in the field plan and analyze data on cell via-
bility, cytotoxicity or RNA sequencing and compare results with the data provided here. 
1. Data Description 
01_Viability_Cytotoxicity_Figures provides the graphs on the live/dead ratios of iPSC-DSN from
two healthy donors exposed to six different chemotherapeutic drugs. The live/dead ratios nor-
malized to vehicle and the respective curves are provided in this file. All graphs are numbered
from 1 to 81 which allow reference to the raw data, which are provided below. 
02_Viability_Cytotoxicity_Assays provides the calculated live/dead ratios of all cell viability and
cytotoxicity assays that were performed in [1] . This Excel-file provides 17 sheets: The first sheet
includes a table that briefly lists all assays performed, how many wells had to be excluded from
further analyses and the reason for exclusion. The following 15 sheets provide the live/dead ra-
tios from all assays that were shown in the figures of the file above and in the Supplementary
Figs. 5–19 of [1] . This file also provides pictures of the cell culture plates and the viability curves.
The raw data from which the live/dead ratios were calculated and the precise steps for their cal-
culation are provided in the folder below ( 03_Viability_Cytotoxicity_Assays_Raw_Data ), with excel
files of which the respective numbers match the graphs in 01_Viability_Cytotoxicity_Figures and
the assays in 02_Viability_Cytotoxicity_Assays. 
03_Viability_Cytotoxicity_Assays_Raw_Data is a folder which contains 81 excel files with the
raw and analyzed data of all assays performed in [1] . Each of these excel files consists of at
least three sheets which are called MTT, Cytotox and Combined , and in in some cases also Com-
bined_corrected . In the upper part of each sheet, the comma-separated values extracted from the
.csv files of the assay readers are shown. Below, these values are put into a table in which the
percentage relative to vehicle are calculated. The sheet Combined_Corrected shows the data af-
ter exclusion of the wells that did not pass microscopic quality control: e.g., if contamination
with fibroblasts or fungus were to be found (usually marked with a red square and a dot in
the middle on the plate) or if the cells were detached (usually marked with an x , see respective
documentation in the foto of the plate). Statistical outliers ( ≥ 2 SDs in comparison to the av-
erage of the other wells in the same row) are marked red in the sheet Combined and excluded
from further analyses in the sheet Combined_corrected . The latter also shows the graphs which











































d  re found in the file 01_Viability_Cytotoxicity_Figures. The exact calculation steps can be followed
y clicking on the line with the respective result in the excel file. The graphical and statistical
nalyses are provided in the Graphpad Prism File 04_All _MTT_Cytotoxicity_Assays. 
04_All _MTT_Cytotoxicity_Assays provides the Graphpad Prism file on how the calculations of
ll 81 assays were performed. By clicking on the graphs in the Layouts section, the respective
gures can be found, and their graphical calculation and the respective raw data are linked to
hese layout files. Here, it is also referenced which data are pooled and to be found in the rect-
ngles in 01_Viability_Cytotoxicity_Figures or in the Suppl. Figs. 5–19 in [1] . 
05_MTT_Cytotoxicity_Assays_Manuscript is the Graphpad Prism file, which includes data and
gures presented in the manuscript of [1] and their respective calculation, linked in the Layout
ection . With these s.c. layout files, the live/dead ratios of the cell viability/cytotoxicity assays
re linked, as well as the statistical analyses for the comparison of the cell types of the different
ealthy donors. All data, which are included here, are based on the raw data which are provided
n the files above. To make it easier to track the data for the reader, the Graphpad layouts on
hich the figures in [1] are based have a ∗ in front of their file name. 
06_Diff_Gene_expression provides the table with the differentially expressed genes of iPSC-
SN treated with vehicle (DMSO 1/60 0 0) or paclitaxel 1 μM for 24 h. Furthermore, the TPM file
Transcripts Per Kilobase Million) is included which allows the reader to search 58.0 0 0 genes for
heir mRNA expression in iPSC-DSN treated with vehicle or with paclitaxel. 
07_Diff_Gene_Expression_HTML provides the HTML file with the analyzed comparative data of
PSC-DSN treated with vehicle (DMSO 1/60 0 0) or paclitaxel 1 μM for 24 h. 
08_RNA_seq_DNA_GEO. This file contains the GEO submission form for the RNA sequencing
ata. 
09_RNA_sequencing_GEO_Link. This file provides access to the raw and analyzed transcriptome
ata. 
. Experimental Design, Materials and Methods 
The experimental design, materials and methods are also described in detail in the
anuscript “Modeling chemotherapy induced neurotoxicity with human induced pluripotent
tem cell (iPSC) -derived sensory neurons” [1] and its supplemental methods. 
.1. iPSC lines 
iPSC-derived sensory neurons were differentiated from the established stem cell lines
IHi0 05-A ( https://hpscreg.eu/cell-line/BIHi0 05-A ) and BIHi004-B ( https://hpscreg.eu/cell-line/
IHi004-B , Berlin Institute of Health Stem Cell Core Facility), obtained by reprogramming of hu-
an dermal fibroblasts using Sendai viral vectors as previously reported [ 2 , 3 ]. Cells were cul-
ured on growth factor reduced Geltrex (Gibco) in E8 media with daily media exchange. Cells
ere enzymatically clump-passaged when > 70% confluency was reached, usually every 2–4 days
sing EDTA (UltraPure TM 0.5 M EDTA, Thermo Fisher). 
.2. Sensory neuron differentiation and maintenance 
We applied the s.c. P2 protocol by Schwartzentruber et al. (2018) [4] for human iPSC dif-
erentiation. In brief, confluent iPSC were single cell seeded at a density between 20 0.0 0 0
nd 40 0.0 0 0/well into 6-well plates (Falcon) on growth factor reduced Geltrex (Gibco) and
aintained in E8 media until 70–80% confluency was achieved (usually after 48 to 72 h). On
ay 0, E8 media was exchanged for Knockout Serum Replacement Media (500 ml DMEM-KO
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Fig. 1. Differentiation and characterization of iPSC-DSN. (A) . Cells were maintained in E8 media until differentiation was 
started with LDN19318 and SB431542 (s.c. 2i , dual SMAD inhibition), followed by the activation of WNT using CHIR99021, 
Notch inhibition with DAPT and inhibition of VEGF/FGF/PDGF applying SU5402 (s.c. 3i , when applied together with 2i 
referenced as 5i ). After reseeding on d11, cells matured for at least 30 more days ( maturation phase ). (B–D) show repre- 
sentative phase contrast images of the differentiation phase, from stem cell colonies (B) to sensory neuron ganglia like 
structures > 40d (D). (E–G) depict typical markers of the peripheral nervous system, which is Peripherin in d13 iPSC-DSN 
















[Gibco] supplemented with 130 ml CTS KnockOut SR XenoFree Medium (Gibco), 1 × MEM-Non-
essential Amino Acid Solution (Sigma), 1 × Glutamax (Gibco) and 0.01 mM β-Mercapto-ethanol
(Gibco) including the two small molecule inhibitors ‘2i’: 100 nM LDN-193189 (Sigma) and 10
μM SB-431542 (Peprotech) for neuroectoderm differentiation. On day 3, ‘3i’ consisting of 3 μM
CHIR99021 (Sigma), 10 μM DAPT (Sigma) and 10 μM SU5402 (Sigma) were also added for neu-
ral crest specification. On day 4, N2B27 media (500 ml Neurobasal-Medium [Gibco], 5 ml of
N-2 (100 ×) supplement [Gibco], 10 ml of B27-supplement (50 ×) without Vitamin A [Gibco],
1 × Glutamax and 0.01 mM β-Mercapto-ethanol [Sigma]) was progressively phased in. From
day 7 onwards, ‘2i’ addition was ceased while ‘3i’ continued to be added until day 11 ( Fig. 1
A). On day 11, iPSC-DSN were either reseeded or cryopreserved according to the protocols of
Schwartzentruber et al. [4] and Stacey et al. [5] (also see detailed Suppl. Methods in [1] ). On day
14, the few dividing non-neuronal cells were eliminated applying 1 μg/ml Mitomycin C (Sigma)
for 2 h. iPSC-DSN were maturated for at least four more weeks, with half media changes every
3–4 days using N2B27 supplemented with BDNF, GDNF, βNGF and NT3 (all at 25 ng/ml, Pepro-
tech). For the present study, we performed 12 independent differentiations, carried out by the
same experimenter. 
















































.3. Compound preparation 
Paclitaxel (Adipogen), bortezomib (Cayman Chemical) and 5-fluorouracil (Sigma) were dis-
olved in DMSO. Cisplatin (Sigma) was solved in sterile 0.9% NaCl (all at 6 mM). Vincristine (Cay-
an Chemical), doxorubicin hydrochloride (Tocris) and lithium chloride (Sigma) were prepared
n aqueous solutions using sterile water (stock solutions: 600 mM lithium chloride, vincristine
nd doxorubicin 1 mM). Final concentrations of 1 nM to 100 μM (cisplatin) or 100 pM to 10 μM
all other substances but lithium, which was applied in 10 to 10 0 0 μM concentrations) were ad-
inistered for 24 h for cell viability and cytotoxicity experiments, unless otherwise stated (e.g.,
he lithium experiments were carried out in a 72 h specimen, see [1] ). Vehicle concentrations
ere 1/600 DMSO (for experiments with paclitaxel, bortezomib and 5-fluorouracil), 1/100 NaCl
.9% or water (for experiments with vinristine, doxorubicin) and 1/60 (NaCl 0.9%, experiments
ith cisplatin). As only 1 μM paclitaxel was administered in the RNA sequencing experiments,
he DMSO vehicle was applied in a 1/60 0 0 concentration. 
.4. Cell viability and cytotoxicity assays 
Chemotherapeutic drugs were added to iPSC-DSN maintained in 96-well plates and incu-
ated for 24 h if not otherwise stated. Cell viability and cytotoxicity were assessed using MTT
nd proteases assays (Promega CytoTox-Fluor Assay and CytoTox-Glo Assay), according to the
anufacturers’ instructions. Live/dead ratios of MTT/proteases assays were calculated and nor-
alized to vehicle (compare [ 1 , 6 ]). All raw data of these assays, their calculation to live/dead
atios and their graphical analyses are provided in the following files which are attached to
his article: 01_Viability_Cytotoxicity_Figures (graphical overview; assays are numbered and allow
eference to the raw files), 02_Viability_Cytotoxicity_Assays (calculated live/dead ratios), 03_Viabil-
ty_Cytotoxicity_Assays_Raw_Data (Folder with excel files with MTT and cytotoxicity assays sepa-
ately and the live/dead ratio normalized to vehicle), 04_All _MTT_Cytotoxicity_Assays (Graphpad
ile with the calculation of the graphs of all assays) and 05_MTT_Cytotoxicity_Assays_Manuscript
Graphpad file with the grahps shown in the main figures of [1] ) . 
The z-factor was calculated applying digitonin (200 μg/ml, sigma) for 24 h on iPSC-DSN
13, resulting in a mean value of 0.76 ± 0.13, indicating a large separation band [7] (5 ex-
eriments pooled; see the last sheet of the file 02_Viability_Cytotoxicity_Assays ). Experiments to
valuate lithium chloride as potential neuroprotectant were performed with the same setup,
ut in a 72 h treatment challenge (see 02_Viability_Cytotoxicity_Assays and the folder 03_Viabil-
ty_Cytotoxicity_Assays_Raw_Data) . 
.5. Transcriptome sequencing analyses 
iPSC-DSN were cultured in Geltrex coated 6-well plates at 10 6 cells/well as described above.
fter maturation until d44 - d49, three wells were treated either with vehicle (DMSO at 1/60 0 0)
r paclitaxel (1 μM for 24 h), and RNA was harvested with the Aurum TM Total RNA Mini Kit ac-
ording to manufacturers’ instructions, with a total RNA amount between 1.49 and 2.97 μg. RNA
equencing was conducted by Brooks Life Sciences Genewiz ®, applying PolyA selection for RNA
emoval, 2 × 150 bp sequencing configuration and 20–30 million reads per sample. 5 samples
ere analyzed ( n = 3 treated with DMSO vs. n = 2 treated with paclitaxel). 
Computational Methods. RNA Seq reads were mapped to human genome (GRCh38.p7) with
TAR-version 2.7.3a [8] applying the default parameters. We obtained an average of 80.2%
niquely mapped reads per sample. Reads were assigned to genes with featureCounts [9] with
he following parameters: -t exon -g gene_id, gene annotation - Gencode GRCh38/v25. The dif-
erential expression analysis was carried out with DESeq2-version 1.22.1 [10] using the default
arameters. We kept genes that have at least 5 reads in at least 2 samples. Gene set enrichment
nalysis was carried out with R/tmod package [11] . 






























2.6. Statistical analyses 
Data were analyzed using Prism v8 (Graphpad Software, San Diego, CA). Data were checked
for Gaussian distribution applying histograms and the Shapiro-Wilk normality test. Normally
distributed data were analyzed with two-sided t-tests (2 groups). Data with low sample sizes
or data which were not normally-distributed were analyzed with the Mann-Whitney-U test
(2 groups). Cell viabilities were compared with one-way ANOVA and corrected for multiple
comparison using Holm-Sidak’s multiple comparison test (normally distributed data) or the
Kruskal-Wallis test and corrected using the Dunn’s multiple comparison test (data that were not
normally distributed). Dose-response curves were calculated with non-linear regression mod-
els using GraphPad Prism (s.c. Log inhibitor vs. response, three parameters ). The Graphpad files
which include these calculations in detail are provided in this article (see the files 04_All
_MTT_Cytotoxicity_Assays and 05_MTT_Cytotoxicity_Assays_Manuscript). The calculations can be 
reproduced by clicking on the respective layout file in the Graphpad file which then allows ref-
erence to the raw data and their further processing. All raw data of the assays are shown in the
file 03_Viability_Cytotoxicity_Assays_Raw_Data, with the respective figures of all assays in the file
01_Viability_Cytotoxicity_Figures. 
All experiments with > d40 iPSC-DSN were replicated at least 3 times from at least 2 inde-
pendently differentiated or maturated iPSC-DSN cultures (biological replicates) with 4 technical
replicates for each condition (see detailed description in Suppl. Material 1, Table 1 and Suppl.
Figs. 5–19 in [1] ). Data points with more than two standard deviations from the sample mean
were treated as statistical outliers and excluded from analysis, which was the case in 1.66% of
the analyzed wells (See Suppl. Mat. 1, Table 1 in [1] or the files provided with this article:
02_Viability_Cytotoxicity_Assays, 03_Viability_Cytotoxicity_Assays_Raw_Data ). Normally distributed 
data are presented as mean ± SD. Not normally distributed data are shown as median with in-
terquartile ranges. Results for all 81 analyzed assays are shown in Suppl. Mat. 1, Figs. 5–19 of
[1] or as Figs. 1–15 attached to this Data-in-Brief article (see 01_Viability_Cytotoxicity_Figures) . 
2.7. Data availability 
Open data publishing guidelines were followed. Raw data of cell viability and cytotoxicity
assays are attached to this Data-in-Brief article. RNA sequencing data discussed in this publica-
tion have been deposited in NCBI’s Gene Expression Omnibus [12] and are accessible through
GEO Series accession number GSE173610 ( https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= 
GSE173610 ). The respective download sources are provided in GEO under the link above: Raw
data are available in SRA, and processed data are available on Series record. 
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including the approval for the use of the cell lines BIHi0 05-A and BIHi0 04-B is deposited un-
der the following links: https://hpscreg.eu/cell- line/BIHi005- A and https://hpscreg.eu/cell-line/
BIHi004-B . 
Declaration of Competing Interest 
The authors report no conflict of interest. 










































RediT Author Statement 
Christian Schinke: Conceptualization, Formal analysis, Funding acquisition, Investigation,
riting – original draft, Writing – review & editing; Valeria Fernandez Vallone: Conceptual-
zation, Funding acquisition, Investigation, Supervision, Writing – review & editing; Andranik
vanov: Investigation, Writing – review & editing; Yangfan Peng: Investigation, Writing – re-
iew & editing; Péter Körtvelyessy: Conceptualization, Resources, Writing – review & editing;
uca Nolte: Investigation, Writing – review & editing; Petra Huehnchen: Conceptualization,
ormal analysis, Writing – original draft, Writing – review & editing; Dieter Beule: Writing –
eview & editing; Harald Stachelscheid: Conceptualization, Resources, Writing – review & edit-
ng; Wolfgang Boehmerle: Conceptualization, Funding acquisition, Formal analysis, Supervision,
riting – original draft, Writing – review & editing; Matthias Endres: Conceptualization, Fund-
ng acquisition, Supervision, Writing – original draft, Writing – review & editing. 
cknowledgments 
We thank Petra Loge for her excellent technical assistance, and Kristin Fischer, Judit Küchler
nd Tanja Fisch of the BIH Stem Cell Core Facility for their invaluable help in stem cell culture
nd maintenance. We thank Dr. Dorette Freyer for sharing her extensive cell culture expertise,
r. Richard Kovács and Dr. Gisela Laettig for their support optimizing Ca 2 + imaging experiments,
nd Smilla Maierhof for her support in cell culture maintenance and intellectual input in the fi-
al phase of the study. This research was supported by the Deutsche Forschungsgemeinschaft
NeuroCure Excellence Cluster to ME) and AnimalFreeResearch Switzerland to CS, WB and ME.
his work was supported by Charité 3R - Replace - Reduce – Refine. ME receives funding from
he Bundesministerium für Bildung und Forschung (Center for Stroke Research Berlin), the Ger-
an Center for Neurodegenerative Diseases (DZNE), the German Center for Cardiovascular Re-
earch (DZHK) and the Corona Foundation. CS, PH and WB are members of the Clinician Scientist
rogram funded by the Charité Universitätsmedizin Berlin and Berlin Institute of Health. PH is
he recipient of a Rahel-Hirsch fellowship funded by the Charité Universitätsmedizin Berlin. 
upplementary Materials 
Supplementary material associated with this article can be found in the online version at
oi: 10.1016/j.dib.2021.107320 . 
eferences 
[1] C. Schinke , V. Fernandez Vallone , A. Ivanov , Y. Peng , P. Körtvelyessy , L. Nolte , P. Huehnchen , D. Beule ,
H. Stachelscheid , W. Boehmerle , et al. , Modeling chemotherapy induced neurotoxicity with human induced pluripo-
tent stem cell (iPSC) -derived sensory neurons, Neurobiol. Dis. 155 (2021) 105391 . 
[2] A.F. Hennig , U. Rössler , F. Boiti , M. Von Der Hagen , M. Gossen , U. Kornak , H. Stachelscheid , Generation of a human
induced pluripotent stem cell line (BIHi002-A) from a patient with CLCN7-related infantile malignant autosomal
recessive osteopetrosis, Stem Cell Res. 35 (2019) 101367 . 
[3] N. Fusaki , H. Ban , A. Nishiyama , K. Saeki , M. Hasegawa , Efficient induction of transgene-free human pluripotent
stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome, Proc.
Jpn. Acad. Ser. B 85 (8) (2009) 348–362 . 
[4] J. Schwartzentruber , S. Foskolou , H. Kilpinen , J. Rodrigues , K. Alasoo , A.J. Knights , M. Patel , A. Goncalves , R. Ferreira ,
C.L. Benn , et al. , Molecular and functional variation in iPSC-derived sensory neurons, Nat. Genet. 50 (1) (2018)
54–61 . 
[5] P. Stacey , A.M. Wassermann , L. Kammonen , E. Impey , A. Wilbrey , D. Cawkill , Plate-based phenotypic screening for
pain using human iPSC-derived sensory neurons, SLAS Discov. Adv. Life Sci. R&D 23 (6) (2018) 585–596 . 
[6] D. Von Der Ahe , P. Huehnchen , M. Balkaya , S. Peruzzaro , M. Endres , W. Boehmerle , Suramin-induced neurotoxicity:
preclinical models and neuroprotective strategies, Molecules 23 (2) (2018) 346 . 
[7] J.H. Zhang , T.D.Y. Chung , K.R. Oldenburg , A simple statistical parameter for use in evaluation and validation of high
throughput screening assays, J. Biomol. Screen 4 (2) (1999) 67–73 . 






[8] A . Dobin , C.A . Davis , F. Schlesinger , J. Drenkow , C. Zaleski , S. Jha , P. Batut , M. Chaisson , T.R. Gingeras , STAR: ultrafast
universal RNA-seq aligner, Bioinformatics 29 (1) (2013) 15–21 . 
[9] Y. Liao , G.K. Smyth , W. Shi , featureCounts: an efficient general purpose program for assigning sequence reads to
genomic features, Bioinformatics 30 (7) (2014) 923–930 . 
[10] M.I. Love , W. Huber , S. Anders , Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2,
Genome Biol. (12) (2014) 15 . 
[11] J. Zyla , M. Marczyk , T. Domaszewska , S.H.E. Kaufmann , J. Polanska , J. Weiner , Gene set enrichment for reproducible
science: comparison of CERNO and eight other algorithms, Bioinformatics 35 (24) (2019) 5146–5154 . 
[12] R. Edgar , Gene expression omnibus: NCBI gene expression and hybridization array data repository, Nucleic Acids
Res. 30 (1) (2002) 207–210 . 
